<DOC>
	<DOC>NCT00904449</DOC>
	<brief_summary>The purpose of this study is to monitor the long-term analgesic effectiveness, safety, and utility of oxymorphone ER for the relief of moderate to severe pain due to cancer.</brief_summary>
	<brief_title>Open Label Assessment of Long-Term Safety and Utility</brief_title>
	<detailed_description />
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>Males or females aged &gt; 18 years with moderate to severe pain arising from cancer (histologically and/or clinically proven) who require chronic treatment with WHO step 3 analgesics. Women of childbearing potential must be using an approved method of contraception (hormone contraception, IUD, or double barrier method) and have a negative serum pregnancy test prior to entry into the study. Participated in study EN3202018; the patient must have been treated with study medication and completed the exit visit to be eligible. Experienced a serious, adverse experience during study EN3202018 that was possible or probably related to study medication. Withdrew from study EN3202018 due to an Adverse experience possibly or probably related to study medication. Known idiosyncratic reaction or hypersensitivity to oxymorphone. Inability to take oral medication for 1 week. Patients with ileosomy, mechanical intestinal obstruction, partial or complete gastric outlet obstruction, parlayticileus, or other conditions that might contraindicate the use of, or impair the absorption of an oral controlledrelease dosage form.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>